Outpatient treatment of COVID-19: Impact of comorbidities on hospital admissions and other treatment decisions

Recruiting

• Conditions: B97.2; Coronavirus as the cause of diseases classified to other chapters

• Registration Number: DRKS00023014
• Lead Sponsor: IGES Institut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Pediatric and adult patients aged =14 years
• Written consent to participate in the study
• SARS-CoV-2 infection confirmed by laboratory testing
• Sufficient communication skills in the German language
• The patient must be able to recognize the nature, significance and scope of the study/registry and be able to orientate his/her will accordingly
• PC/Tablet/Smartphone with Internet access

Exclusion Criteria

• Missing declaration of consent
• Age <14 years
• Cognitive or communicative limitations that make it impossible to consent to participate in the study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the study is to assess the influence of comorbidities on the need for hospitalization of patients with SARS-CoV-2 in an outpatient setting. It will also be investigated whether and to what extent a change in the current concomitant medication can be observed. Furthermore, the course of COVID-19, comorbidities and related treatment decisions in COVID-19 patients will be described. Finally, it will be determined which other clinical markers can be used as predictors for a<br>severe course of COVID-19 disease can be identified.<br>

Secondary Outcome Measures

Name	Time	Method
Hospitalizations, changes in the treatment of concomitant diseases, the clinical course of COVID-19, the occurrence of symptoms, and laboratory markers of active infection